Castle Creek Biosciences
2 known investors
Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.
BiotechDeep TechMedical Devices
Founders & leadership
MG
Matthew GantzPresident and Chief Executive Officer
DC
David Chu
MT
Michael Townsley
CJ
Christopher J. Larson
RW
Rhea Williams
MC
Matthew Crabtree
RB
Robin Blumenthal
Investors · 2
In the news
- Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciencesglobenewswire.com · 2025
- Castle Creek Biosciences raises US $112.8 million - Cure EBcure-eb.org · 2022
- Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipelineparagonbiosci.com · 2022
- Castle Creek Biosciences - 2025 Funding Rounds & List of Investors - Tracxntracxn.com · 2021
- Castle Creek Biosciences Announces $75 Million Investment to Advance Development of Multiple Gene Therapy Candidates for Rare Diseasesglobenewswire.com · 2020
- Castle Creek Biosciences Raises $75M in Funding - FinSMEsfinsmes.com · 2020